ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
AD-RIDDLE, funded by the Innovative Health Initiative, a European Union public privative partnership, brings together academics, healthcare providers, pharmaceutical companies, regulatory bodies to develop tools and resources for healthcare providers.
Lecanemab represents the first antibody treatment for Alzheimer’s disease to have received traditional approval from the Food and Drug Administration in the US.
Her Royal Highness Princess Muna Al Hussein is the fourth global Ambassador of ADI, joining Queen Silvia of Sweden, Queen Sofia of Spain and the Luis Guillermo Solís Rivera, former President of Costa Rica.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
ADI member Dementia Australia has developed an app to help support brain health and encourage more timely dementia diagnoses.
As ADI prepares to attend the G7 summit in Hiroshima, Japan, DY Suharya writes about the journey of making dementia a priority at the G7 summit.
The month of March has marked significant progress in the development and implementation of National Dementia Plans (NDPs), with the #WhatsYourPlan campaign leading to the launch of plans in Uruguay and Armenia, bringing the total number of WHO Member States with NDPs to 41.
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.